tirzepatide hypoglycemia Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review Tirzepatide outcompetes long-acting insulin in

Phase 2 (24-week) study of ASC30, an investigational small-molecule GLP-1 receptor agonist designed as an ultra-long-acting subcutaneous depot therapy for obesity

This guide assumes a 10 mg vial

If you feel you are not meeting your health goals on your prescribed dose, contact your prescriber

ChristianaCare study finds most patients can continue GLP-1 drugs before gynecologic surgery WILMINGTON Most patients taking widely used weight-loss and diabetes medications can safely continue those drugs before gynecologic surgery, according to a new journal article from ChristianaCare published in Obstetrics & Gynecology

Designed for men aged 25 and above with a BMI of 25+, Fella delivers a comprehensive, guided, and confidential experience